35 completed, 11 terminated, 5 recruiting, 4 unknown. 24 Phase 2, 11 Phase 1, 8 Not applicable, 6 Phase 3, 2 Early Phase 1.
Follow Myelodysplasia: new trials by email Literature Review of Myelodysplasia trials Research Report on Myelodysplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation - Leukemia, Myelodysplasia | Phase 2 | Recruiting | Hannah Choe, MD | 124 | 2026-01-14 | 2026-09-02 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Fludarabine, Busulfan, Melphalan - Hematologic Malignancy, Acute Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 70 | 2023-05-11 | 2026-04-06 |
| MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) - Leukemia, Acute Myeloid Leukemia in Remission | Not applicable | Recruiting | Medical College of Wisconsin | 40 | 2023-05-01 | 2026-05-13 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) RITA (App) - Multiple Myeloma, Solitary Plasmacytoma | Not applicable | Completed | Advice Pharma Group srl | 124 | 2022-06-04 | 2024-11-06 |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy Standard - Metastatic Cancer, Cancer, Breast | Unknown | Weprom | 150 | 2022-06-01 | 2022-05-03 | |
| Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) MGTA-117 - Acute Myeloid Leukemia, Myelodysplasia | Phase 1 | Terminated | Magenta Therapeutics, Inc. | 22 | 2022-02-14 | 2023-02-09 |
| Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis Blood samples - Thrombocytopenia, Immune Thrombocytopenia | Not applicable | Recruiting | University Hospital, Bordeaux | 225 | 2021-05-19 | 2026-06-01 |
| ATG Plus PTCy vs ATG for CGVHD Prophylaxis Cyclophosphamide, Anti-Thymocyte globulin (rabbit) - Acute Leukemia, Myelodysplasia | Phase 2 | Active not recruiting | McMaster University | 80 | 2020-10-14 | 2025-05-11 |
| Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS Haplo SCT with NK cells, Haplo SCT - Acute Myeloid Leukemia, Myelodysplasia | Phase 2 | Terminated | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 6 | 2020-01-15 | 2023-10-04 |
| TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate - Acute Leukemia, Chronic Myelogenous Leukemia (CML) | Phase 3 | Completed | Medical College of Wisconsin | 431 | 2019-06-25 | 2024-04-04 |
| Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT Oral azacitidine, Matched placebo - Acute Myeloid Leukemia, Myelodysplasia | Phase 3 | Completed | University of Birmingham | 326 | 2019-06-14 | 2026-08-14 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Intravenous (IV) and oral Vitamin C - Lymphoid Leukemia, Myeloid Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 61 | 2018-10-01 | 2023-11-07 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders HSCT with TBI Regimen, HSCT with Non-TBI Regimen - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 300 | 2018-03-30 | 2026-06-25 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia CliniMACS® TCRαβ/CD19 Combined Depletion System - Myelodysplasia, Hematologic Malignancy | Phase 1 / Phase 2 | Active not recruiting | Nationwide Children's Hospital | 20 | 2018-03-02 | 2026-04-03 |
| Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents Deferasirox - Myelodysplasia | Phase 2 | Completed | University Hospital, Grenoble | 39 | 2018-02-20 | 2024-12-16 |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Unmanipulated UCB, SR-1 UCB - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2017-04-01 | 2017-12-05 | |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 200 | 2016-12-01 | 2026-05-20 |
Showing 20 of 60. Sign in to see all of them.
Anemia, Refractory, with Excess of Blasts (60) · Leukemia, Myeloid, Acute (30) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (23) · Leukemia (14) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Lymphoma (12) · Hodgkin Disease (11) · Hematologic Neoplasms (10) · Multiple Myeloma (10) · Lymphoma, Non-Hodgkin (9) · Neoplasms, Plasma Cell (9) · Primary Myelofibrosis (9) · Anemia, Aplastic (6) · Lymphoma, Mantle-Cell (5)
Anemia (60) · Bone Marrow Diseases (60) · Hematologic Diseases (60) · Hemic and Lymphatic Diseases (60) · Anemia, Refractory (59) · Myelodysplastic Syndromes (59) · Neoplasms (47) · Neoplasms by Histologic Type (46) · Immune System Diseases (42) · Immunoproliferative Disorders (38) · Lymphatic Diseases (38) · Lymphoproliferative Disorders (37) · Leukemia, Myeloid (34) · Leukemia (31) · Pathologic Processes (31)
Cyclophosphamide (11) · fludarabine (10) · Mycophenolic Acid (6) · Tacrolimus (6) · Busulfan (5) · Whole-Body Irradiation (5) · Melphalan (4) · thymoglobulin (4) · Antilymphocyte Serum (3) · Cyclosporine (3) · Granulocyte Colony-Stimulating Factor (3) · Methotrexate (3) · fludarabine phosphate (3) · Azacitidine (2) · Basiliximab (2)
Masonic Cancer Center, University of Minnesota (5) · University of California, San Francisco (5) · David Rizzieri, MD (3) · Indiana University (3) · Duke University (2) · Medical College of Wisconsin (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · University Health Network, Toronto (2) · University Hospital, Grenoble (2) · AbbVie (prior sponsor, Abbott) (1) · Advice Pharma Group srl (1) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · Beth Israel Medical Center (1) · Brown University (1)
United States (41) · France (5) · Canada (4) · Italy (4) · Australia (2) · United Kingdom (2) · Spain (1)
David Rizzieri, MD (4) · Thomas G. Martin, M.D. (4) · Mark Minden, MD (2) · Mary Horowitz, MD (2) · Robert Nelson, MD (2) · Alessandro Flavio Ferri (1) · Alessandro Rambaldi, MD (1) · Andrea Bacigalupo, Prof (1) · Brandon Triplett, MD (1) · Charles A. Linker, M.D. (1) · Charles Craddock (1) · Christine Duncan, MD (1) · Claudio Brunstein, MD (1) · Daniel J. DeAngelo, MD, PhD (1) · Daniela Cilloni, MD (1)
PMID 16423993, PMID 18850014, PMID 19528536, PMID 22009536, PMID 23270493, PMID 24269380, PMID 25933833, PMID 28257476, PMID 30824040, PMID 31375516, PMID 33811823, PMID 34847232, PMID 34855460, PMID 34872106, PMID 36823396, PMID 37196637, PMID 38017103, PMID 38702786, PMID 39283025, PMID 39752608, PMID 40305657, PMID 41894682, PMID 42629427
U01HL069294 (2), 2008 (1), U10CA031946 (1), U10HL069294 (1)